Charles River Laboratories International, Inc. revised financial guidance for 2024. For the period, the company expects revenue growth to be 1.0% to 4.0% compared to previous guidance of 1.0% to 4.0%, organic revenue growth of 0.0% to 3.0% compared to previous guidance of 0.0% to 3.0%, GAAP EPS estimate $7.60 to $8.10 compared to previous guidance of $7.90-$8.40.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
223.1 USD | +0.65% | -2.34% | -5.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.81% | 11.42B | |
+41.40% | 50.93B | |
-0.41% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.90% | 26.02B | |
-21.80% | 18.9B | |
+7.04% | 13.21B | |
+24.55% | 12.17B | |
+30.02% | 12.16B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Revises Financial Guidance for 2024